文章摘要

文章信息/Info

Title:: Efficacy and safety of Natroparin in patients undergoing percutaneous coronary intervention

作者:: 纪辉; 金丽娟; 李学奇; 陈松; 哈尔滨医科大学附属第四医院心内科，黑龙江哈尔滨 150000

Author(s):: JI Hui; JIN LIjuan; LI Xueqi; CHEN Song; Department of Cardiology, Fourth Affiliated Hospital, Harbin Medical University, Haerbin 150000, Heilongjiang, China

关键词:: 肝素; 那屈肝素; 经皮冠状动脉介入治疗; 主要心脏事件

Keywords:: Heparin ; natroparin; percutaneous coronary intervention; major adverse cardiac event

分类号:: R5414

DOI:: -

文献标识码:: A

摘要:: 目的探讨那屈肝素在经皮冠状动脉介入治疗(PCI) 中应用的有效性和安全性。方法将我院2005年5月至2006 年1月收治的共172例行PCI 术的患者分为2组。A 组为PCI 术中用那屈肝素(0.1 ml/10 kg),B 组为PCI术中用普通肝素(133 μkat,1 μkat=60 u)。A 组87 (男62,女25)例,年龄(63±3) 岁。B 组85 (男71,女14) 例,年龄(62±2) 岁。PCI前静脉注射那屈肝素或普通肝素。A组和B组又分别分为择期和急诊PCI。出血程度的判断根据TIMI研究的标准进行。观察所有患者的心脏事件（死亡、再梗死、血运重建）。结果两组的一般临床资料比较差异无显著性。A 组与B 组手术成功率(100 % vs 100%) ; 30 d内主要心血管不良事件比较两组差异均无显著性；在轻微出血方面那屈肝素显著低于普通肝素组 (P<0.05)。结论那屈肝素在急性心肌梗死患者行PCI 术中的应用是有效的、安全的。

Abstract:: AIM To investigate the effectiveness and safety of using Natroparin in PCI. METHODS One hundred and seventytwo PCI patients, who were hospitalized from May 2005 to January 2006 in the Fourth Affiliated Hospital of Harbin Medical University, were randomly divided into two groups. Natroparin was used in group A (87 patients: 62 males and 25 females, average age 63 ±3) and common unfractionated heparin was used in group B (85 patients 71： males and 14 females, average age 62±2). Before PCI, patients in group A were intravenously given Natroparin ( 0.1 ml/10 kg) while those in group B was intravenously given unfractionated heparin (133 μkat) for procedural anticoagulation. Bleeding complications were classified according to Thrombolysis in Myocardial Infarction (TIMI) criteria and the bleeding indexes (changes in hemoglobin) were calculated. All the patients were followed up for major adverse clinical events (MACE) such as death, myocardial infarction and need for revascularization for 30 days after PCI. RESULTS No significant difference was found in baseline characteristics between the two groups. The success rate of operation in both groups was 100% (100 % vs 100%). For the 30day followup, there was no significant difference in MACE between the two groups but minor hemorrhage in Natroparin group was significantly lower than that in unfractionated heparin group. CONCLUSION The application of Natroparin in PCI is safe and effective.

参考文献/References

［1］Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention ［J］. J Am Coll Cardiol, 2002,40(11):1943-1950.

［2］Kereiakes DJ,Grines C,Fry E,et al.Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention［J］. J Invasive Cardiol,2001,13(4):272-278.

［3］Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in highrisk patients with nonSTsegment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide［J］. Circulation，2003,107(2):238-244.

［4］张晓玲，陈方，高阅春,等. 低分子肝素在经皮冠状动脉成形术中的应用［J］. 中国介入心脏病学杂志,2005,13（1）：23-24.

［5］朱建华, 邱原刚, 陈君柱,等. 经皮冠状动脉介入治疗中静脉注射那屈肝素的抗血栓疗效及安全性评价［J］. 中华心血管病杂志, 2005,33(4):335-339.

［6］Hirsh J,Levine MN.Low molecular weight heparin［J］. Blood,1992,79(1):1-17.

［7］Hirsh J, Warkentin TE, Raschke R, et al. Heparin and lowmolecularweight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety［J］. Chest,1998，114（5）:489-510.

［8］Montalescot G,Philippe F,Ankri A,et al.Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery diseas beneficial effects of enoxaparin.French Investigators of the ESSENCE Trial［J］. Circulation,1998,98(4):294-299.

［9］Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and IIb/IIIa antagonists in acute coronary syndromes: final results of the National Investigatorsi Collaborating on Enoxaparin3 (NICE 3) study［J］. Am Heart J, 2003,146（4） :628-634.

我们的网站为什么显示成这样？

那屈肝素在冠状动脉介入治疗中的效果和安全性(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics